


CERTIFICATE OF EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as **Express Mail No.: EL 852434548 US** in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name Margaret D. Pierce

Signature



Date

March 22, 2001

PRELIMINARY AMENDMENT

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket
Confirmation No.

6510-107 CON

First Named Inventor

Bistrup, et al.

Application Number

Unassigned

Filing Date

(Herewith) March 22, 2001

Group Art Unit

Unassigned

Examiner Name

Unassigned

Title

Glycosyl Sulfotransferase-3

Sir:

This is a preliminary amendment to the patent application identified above. Prior to examination of the subject application, please enter the amendments to the specification and claims set forth herein.

AMENDMENTS**IN THE SPECIFICATION**

On page 1 after the title, please insert the following text:

-- CROSS-REFERENCE

This application is a continuation of Serial No. 09/045,284, filed March 20, 1998, which is incorporated herein by reference in its entirety and to which application we claim priority. --

IN THE CLAIMS

Please cancel originally filed claims 1-29 without prejudice to renewal.

Please enter new claims 30-56, as shown below.

--

30. (New) A fragment of at least about 25 contiguous nucleotides of the nucleotide sequence set forth in SEQ ID NO:01.

31. (New) An isolated nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:01, or its complementary sequence.

32. (New) An expression vector comprising the nucleic acid of claim 31.
33. (New) An isolated host cell comprising the expression vector of claim 32.
34. (New) The host cell of claim 33, wherein the cell is prokaryotic.
35. (New) The host cell of claim 33, wherein the cell is eukaryotic.
36. (New) A method of producing a glycosyl sulfotransferase-3 polypeptide, said method comprising:
growing a cell according to claim 33, whereby said polypeptide is expressed; and
isolating said polypeptide substantially free of other proteins.
37. (New) An isolated nucleic acid comprising a sequence which encodes a fragment of at least about 15 contiguous amino acids of the sequence depicted in SEQ ID NO:02, wherein said fragment comprises a sulfate acceptor binding site of glycosyltransferase-3.
38. (New) The nucleic acid of claim 37, wherein said acceptor binding site-encoding sequence comprises amino acids 50 to 78 of SEQ ID NO:02.
39. (New) An expression vector comprising the nucleic acid of claim 37.
40. (New) An isolated host cell comprising the expression vector of claim 37.
41. (New) The host cell of claim 40, wherein the cell is prokaryotic.
42. (New) The host cell of claim 40, wherein the cell is eukaryotic.
43. (New) A method of producing a polypeptide comprising a sulfate acceptor binding site of glycosyl sulfotransferase-3, said method comprising:
growing a cell according to claim 40, whereby said polypeptide is expressed; and
isolating said polypeptide substantially free of other proteins.

44. (New) An isolated nucleic acid comprising a sequence which encodes a fragment of at least about 15 contiguous amino acids of the sequence depicted in SEQ ID NO:2, wherein said fragment comprises a sulfate donor binding site of glycosyltransferase-3.

45. (New) The nucleic acid of claim 44, wherein said donor binding site comprises the amino acid sequence Val-Arg-Tyr-Glu-Asp-Leu (SEQ ID NO:9).

46. (New) An expression vector comprising the nucleic acid of claim 44.

47. (New) An isolated host cell comprising the expression vector of claim 46.

48. (New) The host cell of claim 47, wherein the cell is prokaryotic.

49. (New) The host cell of claim 47, wherein the cell is eukaryotic.

50. (New) A method of producing a polypeptide comprising a sulfate donor binding site of glycosyltransferase-3, said method comprising:
growing a cell according to claim 47, whereby said polypeptide is expressed; and
isolating said polypeptide substantially free of other proteins.

51. (New) An isolated nucleic acid comprising at least 25 contiguous nucleotides of the sequence set forth in SEQ ID NO:01.

52. (New) An expression vector comprising the nucleic acid of claim 51.

53. (New) An isolated host cell comprising the expression vector of claim 51.

54. (New) A method of producing a glycosyl sulfotransferase-3 polypeptide or fragment thereof, said method comprising:
growing a cell according to 53, whereby said glycosyl sulfotransferase-3 polypeptide is expressed; and

isolating said glycosyl sulfotransferase-3 polypeptide substantially free of other proteins.

55. (New) An isolated nucleic acid comprising a sequence which encodes a fragment of at least about 15 contiguous amino acids of a polypeptide having at least about 60% amino acid sequence identity to the sequence depicted in SEQ ID NO:02, wherein said fragment comprises a sulfate acceptor binding site of glycosyltransferase-3.

56. (New) An isolated nucleic acid comprising a sequence which encodes a fragment of at least about 15 contiguous amino acids of a polypeptide having at least about 60% amino acid sequence identity to the sequence depicted in SEQ ID NO:02, wherein said fragment comprises a sulfate donor binding site of glycosyltransferase-3. --

REMARKS

Formal Matters

Claims 30-56 are now pending in this application.

Originally filed claims 1-29 are canceled without prejudice to renewal.

New claims 30-56 are added. Support for new claims 30-56 is found in the claims as originally filed, and throughout the specification, in particular at the following exemplary locations: claim 30: page 10, lines 19-23; claim 31: page 12, lines 22-24; claim 37: page 8, lines 15-16 and page 39, line 19; claim 44: page 8, line 17; and claims 55 and 56: page 7, lines 18-20. All other claims find support in the claims as originally filed. Accordingly, no new matter has been added.

Applicants respectfully request entry of the above amendments to the specification and claims prior to examination of the application.


Conclusion

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number 6510-107 CON.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 22, 2001

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231